Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.05 · Revenue $1.28M · 2 analysts
Est. EPS $-0.05 · Revenue $1.57M · 2 analysts
Est. EPS $-0.17 · Revenue $6.26M · 2 analysts
Est. EPS $-0.05 · Revenue $4.60M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $1.6M | +58.9% | 0.0% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-29.7M | +1.1% | -5.1% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +44.9% | -55.1% | +10.4% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -2346.0% | +54.8% | -5.9% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -1817.1% | +37.8% | -5.1% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-18.8M | +47.4% | -39.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -1151.4% | +66.9% | -39.1% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 13.1% | -99.1% | -34.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.21x | +181.5% | +56.3% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $58.6M | +60.0% | +17.3% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.45 vs -0.42 | -5.9% | -0.04 vs -0.05 | +20.0% |
| Revenue Surprise | $1.6M vs $5.2M | -68.6% | $1.7M vs $925000 | +84.6% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | Gilson Michelle | director | Director Stock Option (Right to Buy) | A | 247,200 | $0.80 |
| Aug 1, 2026 | Gilson Michelle | director | Stock Option (right to buy) | — | 12,500 | $7.46 |
| Jul 21, 2026 | IMRAN MIR A | director, 10 percent owner: | Class A Common Stock | A | 36,000 | $0.69 |
| Jul 17, 2026 | Imran Talat | director, officer: Chief Executive Officer | Class A Common Stock | A | 35,000 | $0.72 |
| Jul 17, 2026 | Maestas Nicholas | officer: Chief Financial Officer | Stock Option (Right to Buy) | A | 2,000,000 | $0.70 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Nicholas Maestas | Chief Financial Officer | USD 791,411 | Male | 1980 | Active |
Svai S. Sanford | Chief Financial Officer | USD 791,411 | Male | 1970 | Active |
Kate McKinley | Chief Business Officer | USD 742,372 | Female | 1978 | Active |
Talat Imran | Chief Executive Officer & Director | USD 549,925 | Male | 1982 | Active |
Mir Hashim | Chief Scientific Officer | USD 416,000 | — | 1960 | Active |
Mir A. Imran | Executive Chairman | USD 30,000 | Male | 1957 | Active |
Alireza Javadi | Chief Technical Officer | — | Male | 1984 | Active |
Jesper Hoeiland | Head of Strategy | — | Male | 1960 | Active |
Arvinder Dhalla | Vice President of Clinical Development | — | Female | — | Active |
Bella Vazquez | Senior Vice President of People & Administrative Services | — | Female | — | Active |
Rani Therapeutics NASDAQ: RANI outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity.
~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~ ~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~ ~ Completed a $20 million registered direct offering ~ ~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~ ~ Appointed Nicholas Maestas as Chief Financial Officer and Michelle Gilson to Board of Directors ~ SAN JOSE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.
SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company's management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below:
SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani's new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani.
RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102 No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeutics Phase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity SAN JOSE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today reported positive initial data from the ongoing Phase 1 study of RT-114, an orally administered RaniPill® Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist being developed by ProGen Co., Ltd.
